Incanthera Plc Regulatory News (INC.PL)

 

3 October 2023

Incanthera plc

 

("Incanthera" or the "Company")

 

Notice of Annual General Meeting 2023 and Posting of Annual Report and Accounts

 

Incanthera plc (AQSE: INC), the company focused on innovative technologies in dermatology and oncology, confirms that the Annual Report and Accounts for the year ended 31 March 2023, and the Notice of Annual General Meeting ("AGM") has been posted to the Company's website today.

These documents are available, in electronic form, for download on the Company's website: www.incanthera.com 

 

The Notice of AGM with accompanying Form of Proxy will be posted to shareholders in due course.

 

Incanthera's AGM will be held at 12:00 noon on Wednesday, 8 November 2023 at the offices of Gateley Plc, Ship Canal House, 98 King Street, Manchester, M2 4WU.

 

The Meeting will focus on the formal business of the meeting only.

In order to ensure that all shareholders are able to follow the proceedings of the AGM, the Company will provide access online through the Investor Meet Company platform.  However, shareholders will not be able to vote online during the Meeting and are therefore urged to submit their votes via proxy as early as possible, electronically or by post.

Shareholders are also invited to submit written questions for the Board to consider. Questions can be pre submitted in advance of the AGM via the Investor Meet Company Platform up to 9.00am on 7 November 2023, being the day before the AGM, or via the Investor Meet Platform at any time during the AGM itself.

The Board will respond to key questions during the meeting and will provide such answers on its website thereafter. 

Shareholders who wish to attend the AGM online should register for the event in advance via the following link: 

https://www.investormeetcompany.com/incanthera-plc/register-investor

  

 

For further enquiries:

 

 

                         

Notes to Editors

 

Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions.

 

The Company's current focus is a range of dermatological applications utilising its unique formulation and delivery technologies to meet cosmetic and clinically unmet needs. This range will include the Company's  potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. The Company is currently focussed upon delivering this range to a commercial partner.

 

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions. 

 

Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

                                                                                   

For more information on the Company please visit: www.incanthera.com

 

@incantheraplc

 

END